"Karyotype" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The full set of CHROMOSOMES presented as a systematized array of METAPHASE chromosomes from a photomicrograph of a single CELL NUCLEUS arranged in pairs in descending order of size and according to the position of the CENTROMERE. (From Stedman, 25th ed)
| Descriptor ID |
D059785
|
| MeSH Number(s) |
G05.360.162.679
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Karyotype".
Below are MeSH descriptors whose meaning is more specific than "Karyotype".
This graph shows the total number of publications written about "Karyotype" by people in this website by year, and whether "Karyotype" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 4 | 6 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 4 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Karyotype" by people in Profiles.
-
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma. Gynecol Oncol. 2024 07; 186:110-116.
-
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320.
-
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precis Oncol. 2023 01; 7:e2200400.
-
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv. 2022 06 14; 6(11):3433-3439.
-
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
-
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022 06; 197(6):736-744.
-
Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. Am J Clin Pathol. 2019 10 07; 152(5):675-685.
-
FouNdER mutations confer risk for leukemias. Blood. 2019 06 20; 133(25):2636-2638.
-
Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J. 2019 02 19; 9(3):20.
-
Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Curr Treat Options Oncol. 2019 02 11; 20(2):15.